Pharmacokinetics of Recombinant Human Growth Hormone (rhGH) in Beagles by ELISA

Author(s): Yueyue Qian, Qing Shao, Quanyu Xu, Hongqun Qiao*

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 8 , 2020


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Somatropin is recombinant human growth (GH) used for the treatment of growth failure in children and GH deficiency in adults. At present, rhGH marketed in China is mostly freeze-dried powder injection. As the lyophilization process is unstable, time-consuming and costly, rhGH has been prepared into an aqueous solution for administering directly.

Introduction: In this study, the pharmacokinetics of two dosage forms of rhGH in beagle dogs after single subcutaneous administration was determined by enzyme-linked immunosorbent assay (ELISA).

Methods: Twelve healthy beagles (male, 6:female, 6) were used for the pharmacokinetic study and were equally divided into two groups. Subcutaneous injection of 0.2 IU/kg with rhGH in the two formulations. The blood samples were taken from forearms, 0, 0.033, 0.083, 0.25, 0.5, 1, 2, 3, 4, 7, 10, 24 h and collected the beagle plasma on time. The pharmacokinetic parameters of rhGH after subcutaneous (s.c.) injection were determined experimentally on beagles. Primary PK endpoints were area under the serum concentration-time curve (AUC0-t) and maximum serum concentration (Cmax). Serum rhGH level was determined by enzyme-linked immunosorbent assay.

Results: The calibration curves obtained were linear over the concentration range of 25 to 1600 ng/ml for recombinant human growth. The results of the intra- and inter-day precision and accuracy studies were well within the acceptable limits. The analysis samples were stable under different storage conditions and temperature.

Conclusion: The developed ELISA method has been successfully applied to the studies of pharmacokinetic of recombinant human growth hormone in beagles.

Keywords: Recombinant human growth hormone (rhGH), Pharmacokinetic, ELISA, beagles, dosage form, subcutaneous injection.

[1]
Wong, K-S.; Chan, G.H.M.; Ho, E.N.M.; Wan, T.S.M. Simultaneous detection of recombinant growth hormones in equine plasma by liquid chromatography/high-resolution tandem mass spectrometry for doping control. J. Chromatogr. A, 2016, 1478, 35-42.
[http://dx.doi.org/10.1016/j.chroma.2016.11.032] [PMID: 27914605]
[2]
Osborn, B.L.; Sekut, L.; Corcoran, M.; Poortman, C.; Sturm, B.; Chen, G.; Mather, D.; Lin, H.L.; Parry, T.J. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol., 2002, 456(1-3), 149-158.
[http://dx.doi.org/10.1016/S0014-2999(02)02644-4] [PMID: 12450581]
[3]
Giustina, A.; Veldhuis, J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev., 1998, 19(6), 717-797.
[http://dx.doi.org/10.1210/er.19.6.717] [PMID: 9861545]
[4]
Jørgensen, J.O.L.; Møller, N.; Wolthers, T.; Møller, J.; Grøfte, T.; Vahl, N.; Fisker, S.; Orskov, H.; Christiansen, J.S. Fuel metabolism in growth hormone-deficient adults. Metabolism, 1995, 44(10)(Suppl. 4), 103-107.
[http://dx.doi.org/10.1016/0026-0495(95)90229-5] [PMID: 7476301]
[5]
Mazziotti, G.; Giustina, A. Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol., 2013, 9(5), 265-276.
[http://dx.doi.org/10.1038/nrendo.2013.5] [PMID: 23381030]
[6]
Kyrou, I.; Tsigos, C. Stress hormones: physiological stress and regulation of metabolism. Curr. Opin. Pharmacol., 2009, 9(6), 787-793.
[http://dx.doi.org/10.1016/j.coph.2009.08.007] [PMID: 19758844]
[7]
Høybye, C.; Cohen, P.; Hoffman, A.R.; Ross, R.; Biller, B.M.K.; Christiansen, J.S. Growth Hormone research society. status of long-acting-growth hormone preparations--2015. Growth Horm. IGF Res., 2015, 25(5), 201-206.
[http://dx.doi.org/10.1016/j.ghir.2015.07.004] [PMID: 26187188]
[8]
Chang, S.; Hui, P. Safety of recombinant human growth hormone in treating children with growth hormone deficiency and idiopathic short stature. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2011, 33(2), 123-126.
[PMID: 21529437]
[9]
Stochholm, K.; Kiess, W. Long-term safety of growth hormone-A combined registry analysis. Clin. Endocrinol. (Oxf.), 2018, 88(4), 515-528.
[http://dx.doi.org/10.1111/cen.13502] [PMID: 29055168]
[10]
Jørgensen, J.O.L. Human growth hormone replacement therapy: pharmacological and clinical aspects. Endocr. Rev., 1991, 12(3), 189-207.
[http://dx.doi.org/10.1210/edrv-12-3-189] [PMID: 1935818]
[11]
Jørgensen, J.O.L.; Møller, J.; Møller, N.; Lauritzen, T.; Christiansen, J.S. Pharmacological aspects of growth hormone replacement therapy: route, frequency and timing of administration. Horm. Res., 1990, 33(Suppl. 4), 77-82.
[http://dx.doi.org/10.1159/000181589] [PMID: 2245974]
[12]
Laursen, T.; Jørgensen, J.O.L.; Christiansen, J.S. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults. Clin. Endocrinol. (Oxf.), 1994, 41(3), 337-343.
[http://dx.doi.org/10.1111/j.1365-2265.1994.tb02554.x] [PMID: 7525120]
[13]
Laursen, T.; Jørgensen, J.O.L.; Susgaard, S.; Møller, J.; Christiansen, J.S. Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone. Ann. Pharmacother., 1993, 27(4), 411-415.
[http://dx.doi.org/10.1177/106002809302700402] [PMID: 8477114]
[14]
Lundberg, E.; Andersson, B.; Kriström, B.; Rosberg, S.; Albertsson-Wikland, K. Broad variability in pharmacokinetics of GH following rhGH injections in children. Growth Horm. IGF Res., 2018, 40, 61-68.
[http://dx.doi.org/10.1016/j.ghir.2018.01.004] [PMID: 29422321]
[15]
Janukonyté, J.; Parkner, T.; Lauritzen, T.; Christiansen, J.S.; Laursen, T. Circadian variation in the pharmacokinetics of steady state continuous subcutaneous infusion of growth hormone in adult growth hormone deficient patients. Growth Horm. IGF Res., 2013, 23(6), 256-260.
[http://dx.doi.org/10.1016/j.ghir.2013.09.002] [PMID: 24094495]
[16]
Zhou, L.; Wang, H.Y.; Tong, S.; Okamoto, C.T.; Shen, W.C.; Zaro, J.L. Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery. Biomaterials, 2017, 117, 24-31.
[http://dx.doi.org/10.1016/j.biomaterials.2016.11.051] [PMID: 27923197]
[17]
da Silva Freitas, D.; Mero, A.; Pasut, G. Chemical and enzymatic site specific PEGylation of hGH. Bioconjug. Chem., 2013, 24(3), 456-463.
[http://dx.doi.org/10.1021/bc300594y] [PMID: 23432141]
[18]
Kontermann, R.E. Half-life extended biotherapeutics. Expert Opin. Biol. Ther., 2016, 16(7), 903-915.
[http://dx.doi.org/10.1517/14712598.2016.1165661] [PMID: 26967759]
[19]
Haffner, D.; Schaefer, F.; Girard, J.; Ritz, E.; Mehls, O. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure. J. Clin. Invest., 1994, 93(3), 1163-1171.
[http://dx.doi.org/10.1172/JCI117069] [PMID: 8132756]
[20]
Maack, T. Renal handling of low molecular weight proteins. Am. J. Med., 1975, 58(1), 57-64.
[http://dx.doi.org/10.1016/0002-9343(75)90533-1] [PMID: 1090151]
[21]
Maack, T.; Johnson, V.; Kau, S.T.; Figueiredo, J.; Sigulem, D. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int., 1979, 16(3), 251-270.
[http://dx.doi.org/10.1038/ki.1979.128] [PMID: 393891]
[22]
Christensen, E.I.; Birn, H. Megalin and cubilin: multifunctional endocytic receptors. Nat. Rev. Mol. Cell Biol., 2002, 3(4), 256-266.
[http://dx.doi.org/10.1038/nrm778] [PMID: 11994745]
[23]
Seested, T.; Appa, R.S.; Jacobsen, C.; Christensen, E.I. Recombinant activated factor VII is reabsorbed in renal proximal tubules and is a ligand to megalin and cubilin. Nephron, Exp. Nephrol., 2011, 117(3), e82-e92.
[http://dx.doi.org/10.1159/000321161] [PMID: 20861656]
[24]
Klitgaard, T.; Nielsen, J.N.; Skettrup, M.P.; Harper, A.; Lange, M. Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects. Growth Horm. IGF Res., 2009, 19(6), 463-470.
[http://dx.doi.org/10.1016/j.ghir.2009.02.004] [PMID: 19303337]
[25]
Wang, W. Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm., 2000, 203(1-2), 1-60.
[http://dx.doi.org/10.1016/S0378-5173(00)00423-3] [PMID: 10967427]
[26]
Wahl, V.; Khinast, J.; Paudel, A. Lyophilized protein powders: A review of analytical tools for root cause analysis of lot-to-lot variability. Trends Analyt. Chem., 2016, 82, 468-491.
[http://dx.doi.org/10.1016/j.trac.2016.05.012]
[27]
Hancock, B.C.; Shalaev, E.Y.; Shamblin, S.L. Polyamorphism: a pharmaceutical science perspective. J. Pharm. Pharmacol., 2002, 54(8), 1151-1152.
[http://dx.doi.org/10.1211/002235702320266343] [PMID: 12195833]
[28]
Pearson, D.S.; Smith, G. Dielectric analysis as a tool for investigating the lyophilization of proteins. Pharm. Sci. Technol. Today, 1998, 1(3), 108-117.
[http://dx.doi.org/10.1016/S1461-5347(98)00030-3]
[29]
Desrosiers, P.; O’Brien, F.; Blethen, S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr. Endocrinol. Rev., 2005, 2(Suppl. 3), 327-331.
[PMID: 16456500]
[30]
Kapoor, R.R.; Burke, S.A.; Sparrow, S.E.; Hughes, I.A.; Dunger, D.B.; Ong, K.K.; Acerini, C.L. Monitoring of concordance in growth hormone therapy. Arch. Dis. Child., 2008, 93(2), 147-148.
[http://dx.doi.org/10.1136/adc.2006.114249] [PMID: 17768149]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 8
Year: 2020
Published on: 27 September, 2020
Page: [1112 - 1120]
Pages: 9
DOI: 10.2174/1573412915666190709094740
Price: $65

Article Metrics

PDF: 21
HTML: 1